The Costochondritis market, driven by the increasing global incidence of non-cardiac chest pain, has captured the attention of healthcare stakeholders. Costochondritis, the inflammation of the cartilage connecting the ribs to the breastbone, presents a diagnostic challenge due to its symptoms mimicking more severe cardiac conditions, which often mandates expensive and extensive rule-out procedures in emergency settings. The market's valuation reflects the burden of this condition, with the global Costochondritis market valued at USD 1.39 Billion in 2023, according to industry reports. Key market drivers include the rising prevalence of related inflammatory conditions like arthritis and an increase in physical strain injuries from strenuous activities and sports. North America currently leads the market, primarily due to an established healthcare infrastructure and high diagnosis rates. The market segmentation covers diagnostics, treatment (drugs, therapy, and surgery), and end-users such as hospitals, clinics, and research centers. The demand for anti-inflammatory drugs dominates the treatment segment, propelled by their effectiveness in symptom management. However, market growth faces restraints from the high cost of certain treatments, surgeries, and limitations in medical reimbursement for bone-related diseases. Future expansion is heavily dependent on advancements in diagnostic tools that can offer definitive and rapid differentiation from cardiovascular issues, which would streamline patient care and reduce unnecessary hospital expenditure. This crucial Costochondritis Market analysis will inform strategic decision-making for pharmaceutical, medical device, and healthcare providers.